Precision BioSciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 3, 2026.

Key Highlights

  • Reporting period: The quarterly report covers the three months ended September 30, 2026.
  • Shares outstanding: As of October 29, 2026, the registrant had 27,935,719 shares of common stock, $0.000005 par value per share, outstanding.
  • Filer status: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Exchange listing: The common stock trades on the Nasdaq Capital Market under the symbol DTIL.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • Forward-looking statements: The filing includes forward-looking statements that the company states are subject to known and unknown risks and uncertainties, and actual results may differ materially from those expressed.

Precision BioSciences Q3 2026 Filing: Key Disclosures and Context

Precision BioSciences, Inc. (NASDAQ:DTIL), a Delaware-incorporated biotechnology company headquartered at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, submitted its quarterly report on Form 10-Q for the period ended September 30, 2026. The filing was made under Commission File Number 001-38841 and covers financial statements, management's discussion and analysis, and other required disclosures for the third quarter of fiscal 2026.

According to the filing, the company had 27,935,719 shares of common stock outstanding as of October 29, 2026, with a par value of $0.000005 per share. The company confirmed it has filed all reports required during the preceding 12 months and has submitted all required Interactive Data Files electronically, as indicated by affirmative check marks on the cover page. The registrant identified itself as a non-accelerated filer and a smaller reporting company, and confirmed it is not an emerging growth company.

The filing discloses that the company's operations are centered on its ARCUS genome-editing technology platform. The company identified a range of risk factors, including its ability to procure sufficient funding, its limited operating history, competition in the genome editing and biotechnology fields, and dependence on its ARCUS technology. The forward-looking statements contained in the report, the company noted, "are based on our management's beliefs and assumptions and on information currently available to us" and are subject to risks and uncertainties that could cause actual results to differ materially.

What Was Disclosed

Precision BioSciences filed a Form 10-Q for the quarter ended September 30, 2026, reporting 27,935,719 common shares outstanding as of October 29, 2026, its non-accelerated and smaller reporting company status, and its continued focus on ARCUS genome-editing technology.